Our Team


Leroy Hood, M.D., Ph.D., Founder and Board Chair

Dr. Leroy Hood is Co-Founder, Professor and Chief Strategy Officer at the Institute for Systems Biology and Senior Vice President and Chief Science Officer at Providence St. Joseph Health.  He received his MD from Johns Hopkins Medical School in 1964 and his PhD in biochemistry from Caltech in 1967.  He was a Senior Investigator at the Immunology Branch of the National Cancer Institute from 1967-1970.  He then went to Caltech as professor of biology and remained there for 22 years, the last 10 as chair of the department.  His laboratory focused on molecular immunology and technology development during that time—and his lab helped develop the automated DNA and protein sequencers and synthesizers.  Hood co-founded Applied Biosystems 1981 to commercial these instruments.

In 1992 with the help of Bill Gates, Hood moved to Seattle and created the first cross-disciplinary department of Molecular Biotechnology at the University of Washington Medical School.  In 2000, Hood resigned from the UW to start the first systems-biology organization--the Institute for Systems Biology (ISB) where he remained as president until 2018.  He is now Chief Strategy Officer of ISB.  He applied systems thinking to both biology and disease and conceptualized systems medicine, a healthcare that is predictive, preventive, personalized and participatory (P4 medicine), and scientific (quantitative) wellness which collectively constitute 21st century medicine.

In 2016 Hood also became Senior Vice President and Chief Science Officer of Providence St. Joseph Health (PSJH) which enabled him to bring 21st century medicine to PSJH, a very large non-profit healthcare system (see 5 million patients/year). Dr. Hood has been elected to all three National Academies—Science, Medicine and Engineering.  Hood has published more than 900 peer-reviewed papers and has 36 patents.  He has won a variety of prizes and awards including the Lasker Award in 1987 for deciphering immune diversity, the Kyoto Prize in 2002 for advanced technologies and he received the National Medal of Science from President Obama in 2013.

Yiwu He, Ph.D., M.B.A.


Global Head of R&D at BGI, CEO of BGI Groups USA

Before joining BGI, Dr. Yiwu He was Senior Program Officer of Discovery and Translation Sciences at the Bill & Melinda Gates Foundation.

He was responsible for biomarker programs and other drug and vaccine development projects at the Discovery and Translational Sciences at the Gates Foundation.  The areas for which he manages the Foundation’s investments include HIV, TB, Pneumonia, Enteric Diarrhea, Polio and other infectious diseases. He also manages multiple R&D programs in China including Next Generation Sequencing partnership with Beijing Genomic Institute, Grant Challenge Exploration with Tsinghua University and HIV/TB drug discovery with Jiao Tong University.

Yiwu is the founder of three US based biotech companies. He also served as the executive board director of International Society of Vaccine, as well as an adjunct professor at University of Science and Technology of China.

Thomas Brown, M.D., M.B.A.

Thomas Brown, MD, MBA serves as Executive Director of the Swedish Cancer Institute (SCI) overseeing all clinical, research, business, and administrative operations for SCI.

Dr. Brown is responsible for overseeing the Institute’s Swedish-based operations and programs throughout the five hospital campuses, along with network development; leading SCI’s vision in Personalized Medicine initiative, strategy, planning, advocacy and execution work; furthering relationship development with the Providence Health & Services network; organizing and leading efforts to reposition SCI for health-care reform; overseeing the Institute’s clinical research efforts and advanced technology initiatives; as well as championing SCI’s fund-raising efforts. Dr Brown also serves as the Co-Chair of the Cancer Leadership Advisory Council Executive Committee for Providence Health & Services (PHS).

Prior to coming to Swedish, Dr. Brown served as professor of medicine and chief operating officer of the University of Arizona Cancer Center. He served on the faculty of the University of Texas MD Anderson Cancer Center for a decade, to include: as a professor in gastrointestinal oncology; deputy head and head ad interim, of the Division of Cancer Medicine; and vice president for extramural programs and international business.  While on the faculty at Duke University, as associate professor of medicine, he led development of the multi-disciplinary GI cancer program and a regional, community-based clinical trial consortium.

He holds a Bachelor of Arts degree from The Johns Hopkins University, and a MBA from Rice University. A graduate of the Medical College of Virginia, Dr. Brown completed an internal medicine residency at the University of Florida and a fellowship in medical oncology at The Johns Hopkins University School of Medicine. Dr. Brown’s clinical practice and research focus has been on therapeutic development in gastrointestinal malignancies. His professional and academic interests include healthcare administration and policy, as well as international healthcare delivery systems.

Dr. Brown has served on numerous institutional, national and international committees and boards;  most recently to include The Marsha Rivkin Center for Ovarian Cancer Research, Officer, Board of Directors; Susan G. Komen, Puget Sound Affiliate, Member, Board of Directors; Value in Cancer Care Initiative at the Hutchinson Institute for Cancer Outcomes Research (HICOR), Member, Organizing Committee. Among numerous honors over his career, Dr. Brown was selected as a Jones Scholar while at Rice University and has been selected for inclusion in Best Doctors of America since 1998.


Mauricio Flores, J.D., Executive Director

Mr. Flores works with P4Mi's Board Chairman, Dr. Leroy Hood to develop a network of integrated P4 Medicine demonstration projects in the United States and globally. Flores is also responsible for engaging other healthcare stakeholders and thought leaders to accelerate the emergence of a P4 Medicine healthcare system that delivers more effective clinical care at lower cost.

A graduate of Harvard Law School, Mr. Flores practiced law for over 30 years with a particular focus on the impact of technological change on society. After clerking for the Chief Justice of the California Supreme Court, he was a partner in two national law firms and the co-founder of a boutique law firm specializing in biomedical intellectual property that integrated scientific and legal expertise in cross-disciplinary teams of lawyers and scientists.

Mr. Flores also has extensive experience in legal, commercial, regulatory and ethics issues impacting medical research institutes, clinical centers, pharmaceutical and medical device companies and healthcare investors. He has tried more than 25 civil cases to a verdict in Federal and California courts as lead counsel and appeared as appellate counsel in numerous state and Federal matters, including a seminal case decided by the United States Supreme Court in June 2005 involving the scope of the Hatch-Waxman Act exemption from patent infringement for FDA-related activities.

George Haddad, M.D., Medical Director and Chief Medical Officer

Dr. Haddad received a combined undergraduate and medical education at the State University of New York at Buffalo.  After gaining early acceptance to medical school, he pursued studies in philosophy, German and ancient Greek, spending his final undergraduate semester at the University of Tuebingen in Germany.  He returned to Germany at the end of his medical studies to finish sub-internships at the Charite Hospital of the Humboldt University in Berlin.

He then received a teaching fellowship in the Department of History of Medicine and Science at Yale University and published papers on history of the germ theory of disease and the poetics of scientific-cultural change in modern German and American medicine.  He also completed his residency in internal medicine at Yale-New Haven Hospital/Yale University School of Medicine.  During his last year of residency, he went to Kazan State Medical University in Russia as a teaching resident.

In 2001 Dr. Haddad moved to Seattle and started his clinical practice as a founding member of the hospitalist team at the Swedish Medical Center.  He pursued his interest in international medical affairs by doing teaching stints in Japan and China.  He also served as Medical Directer of Swedish Executive Health, an intensive preventive health program that was designed  in collaboration with Microsoft Corporation.

Since joining the team at the P4 Medicine Institute, Dr. Haddad has pursued an intense study of systems biology/systems medicine.  His mission is to develop the concrete clinical expression of Leroy Hood's vision for a 21st-century medicine that is predictive, preventive, personalized and participatory.

Qiang, Tian, M.D., Ph.D., Scientific Director and Chief Science Officer

Dr. Tian is a physician scientist who directs the scientific, academic, and global affairs of the P4 Medicine Institute. He is Head of Cancer & Stem Cell Group at the Institute for Systems Biology and an affiliate faculty in the Department of Medicine at University of Washington Medical School. He serves as an overseas advisor for the National Research Center for Translational Medicine (Shanghai).

With a career path traversing clinical medicine, molecular genetics, and systems biology, Dr. Tian is primarily interested in applying the powerful systems approach with the enabling genomics, proteomics, and single cell analysis technologies to address some of the most pressing issues pertaining to human health: cancer and stem cell biology, immunity, and disease biomarker discovery. He directs an interdisciplinary team focusing on translational efforts to dissect clonal origin of cancer heterogeneity and the underlying genomic landscape and molecular mechanism contributing to tumorigenesis and therapeutic responses. Dr. Tian has led the development of gene signature panels for cancer patient stratification, and has elucidated protein interaction networks in key signaling pathways for therapeutic targeting. He also contributed to the definition and molecular characterization of several Th cell subsets. He publishes extensively in high impact journals, and is an inventor of four U.S. patents.

Dr. Tian collegially reaches out to global medical communities to promote Systems Medicine and P4 Healthcare. He and Dr. Hood coined the term “Translational Systems Medicine” and co-founded P4 Healthcare Alliance. Dr. Tian has championed international partnerships with the National Center for Translational Medicine and with Jiahui International Hospital, both in Shanghai. His academic efforts have been continuously supported by federal and foundational grants, including a prestigious award addressing NCI’s provocative questions. Dr. Tian has served as an expert grant reviewer for funding agencies around the world (EU, UK, France, Switzerland, US and China). He co-founded two biotech companies, and is currently President of the Seattle Chinese Biomedical Association.